Randomization was stratified according to the REVEAL Lite 2 risk score ... for worsening pulmonary arterial hypertension to transition into the open-label long-term follow-up study SOTERIA ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH ... risk of death as indicated by a REVEAL Lite 2 risk score of at least 9.

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

US-based pharmaceutical company MSD has reported that the Phase III ZENITH trial of WINREVAIR (sotatercept-csrk) for pulmonary arterial hypertension ... Management (REVEAL) Lite 2.0 risk score ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be ...

Risk stratification scoring systems designed for pulmonary arterial hypertension (PAH ... The analysis included the REVEAL Lite 2 risk score, the REVEAL 2.0 risk score, the European Society ...

"We also await data of the use of sotatercept in post-capillary pulmonary hypertension ([WHO] group 2). If the CADENCE study is positive, this would be a game changer," according to Highland.

6576), ("Foresee") today announced the dosing of the first patient in the Phase 2 pulmonary hypertension-associated interstitial lung disease (PH-ILD) study (WINDWARD study). The WINDWARD study ...